Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma

被引:18
|
作者
Hwang, Insang [1 ]
Jung, Seung Il [1 ]
Nam, Deok-Hyun [1 ]
Hwang, Eu Chang [1 ]
Kang, Taek Won [1 ]
Kwon, Dong Deuk [1 ]
Ryu, Soo Bang [1 ]
机构
[1] Chonnam Natl Univ, Sch Med, Dept Urol, Gwangju 501757, South Korea
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2013年 / 7卷 / 3-4期
关键词
TRANSITIONAL-CELL-CARCINOMA; RENAL PELVIS; LYMPHOVASCULAR INVASION; COMPUTED-TOMOGRAPHY; BLADDER-CARCINOMA; TUMOR LOCATION; CANCER-RISK; RECURRENCE; SURVIVAL; URETER;
D O I
10.5489/cuaj.11236
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: We assess the impact of traditional prognostic factors, tumour location, degree of hydronephrosis and diabetes mellitus (DM) on the survival of patients treated for upper urinary tract urothelial carcinoma (UUTUC). Methods: From January 2004 to March 2010, we analyzed data from 114 patients with UUTUC who underwent nephroureterectomy with a bladder cuff excision. Median patient age was 71 years and median follow-up was 26.5 months. The influence of traditional prognostic factors, including DM, tumour stage, grade, location and degree of hydronephrosis, on recurrence-free survival (RFS) rates were analyzed using Kaplan-Meier analysis and Cox proportional hazards regression model. Results: Among 61 renal pelvis and 53 ureteral tumour cases, recurrence was identified in 71 cases (62.3%). Kaplan-Meier analysis showed that degree of hydronephrosis was associated with RFS (p = 0.001). DM and degree of hydronephrosis were independent factors for RFS in Cox proportional regression analysis (HR=1.8 CI: 1.01-3.55, p = 0.04), (HR= 3.7, CI: 2.0-6.5, p = 0.001). All patients with ureteral tumour had no worse prognosis than those with renal pelvis tumour, but the pT2 patients with ureteral tumour had a worse prognosis than those with renal pelvis tumour with a median RFS of 9 months (range: 2.6-15.3 months) and 29 months (range: 8.0-13.2 months), respectively (p = 0.028). Conclusions: Tumour location is not a factor influencing RFS, except in the pT2 stage. However, severe hydronephrosis is associated with a higher recurrence in UUTUC. Also, DM is related to disease recurrence. Further prospective studies are needed to establish the prognostic significance of DM in large populations.
引用
收藏
页码:E215 / E220
页数:6
相关论文
共 50 条
  • [1] Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma
    Ke, Hung-Lung
    Chang, Lin-Li
    Yang, Sheau-Fang
    Lin, Hui-Hui
    Li, Ching-Chia
    Wu, Deng-Chyang
    Wu, Wen-Jeng
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) : 703 - 709
  • [2] Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma
    Makise, Naohiro
    Morikawa, Teppei
    Kawai, Taketo
    Nakagawa, Tohru
    Kume, Haruki
    Homma, Yukio
    Fukayama, Masashi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 7203 - 7209
  • [3] Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?
    Ng, Casey K.
    Shariat, Shahrokh F.
    Lucas, Steven M.
    Bagrodia, Aditya
    Lotan, Yair
    Scherr, Douglas S.
    Raman, Jay D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (01) : 27 - 32
  • [4] Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract
    Margulis, Vitaly
    Youssef, Ramy F.
    Karakiewicz, Pierre I.
    Lotan, Yair
    Wood, Christopher G.
    Zigeuner, Richard
    Kikuchi, Eiji
    Weizer, Alon
    Raman, Jay D.
    Remzi, Mesut
    Roscigno, Marco
    Montorsi, Francesco
    Bolenz, Christian
    Kassouf, Wassim
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2010, 184 (02) : 453 - 458
  • [5] Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: Experience from a nationwide high-volume center in China
    Zhang, Zheng
    Fang, Dong
    Chen, Xiaopeng
    Li, Xuesong
    Xiong, Gengyan
    Zhang, Lei
    He, Qun
    Zhou, Liqun
    ONCOLOGY LETTERS, 2015, 10 (05) : 3113 - 3122
  • [6] Expression of Stathmin in Localized Upper Urinary Tract Urothelial Carcinoma: Correlations With Prognosis
    Lin, Wei-Chou
    Chen, Shyh-Chyan
    Hu, Fu-Chang
    Chueh, Shih-Chieh
    Pu, Yeong-Shiau
    Yu, Hong-Jeng
    Huang, Kuo-How
    UROLOGY, 2009, 74 (06) : 1264 - 1269
  • [7] Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma
    Messer, Jamie C.
    Terrell, John D.
    Herman, Michael P.
    Ng, Casey K.
    Scherr, Douglas S.
    Scoll, Benjamin
    Boorjian, Stephen A.
    Uzzo, Robert G.
    Wille, Mark
    Eggener, Scott E.
    Lucas, Steven M.
    Lotan, Yair
    Shariat, Shahrokh F.
    Raman, Jay D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (06) : 904 - 908
  • [8] Preoperative risk stratification using plasma fibrinogen levels can predict lymphovascular invasion and poor prognosis in patients with upper urinary tract urothelial carcinoma
    Kuroda, Kenji
    Tasaki, Shinsuke
    Asakuma, Junichi
    Horiguchi, Akio
    Ito, Keiichi
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (05)
  • [9] Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy
    Hurel, Sophie
    Roupret, Morgan
    Seisen, Thomas
    Comperat, Eva
    Phe, Veronique
    Droupy, Stephane
    Audenet, Francois
    Pignot, Geraldine
    Cathelineau, Xavier
    Guy, Laurent
    Cussenot, Olivier
    Ouzzane, Adil
    Bozzini, Gregory
    Nison, Laurent
    Ruffion, Alain
    Colin, Pierre
    WORLD JOURNAL OF UROLOGY, 2015, 33 (03) : 335 - 341
  • [10] Is radiotherapy helpful for the prognosis of upper urinary tract urothelial carcinoma? A meta-analysis
    Zhou, Xiao
    Luo, Guangcheng
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (10) : 424 - 433